Article Text

Download PDFPDF
Platelet-rich plasma: any substance into it?
  1. O Mei-Dan1,
  2. G Mann1,2,
  3. N Maffulli3
  1. 1Department of Orthopaedic Surgery, Sports Injury Unit, Meir University Hospital, Kfar-Saba, Israel
  2. 2Ribstein Centre for Sport Medicine Sciences and Research, Wingate Institute, Netanya, Israel
  3. 3Queen Mary University of London, Centre for Sports and Exercise Medicine, Barts and The London School of Medicine and Dentistry Mile End Hospital, 275 Bancroft Road, London E1 4DG, UK
  1. Correspondence to N Maffulli, Queen Mary University of London, Centre for Sports and Exercise Medicine, Barts and The London School of Medicine and Dentistry Mile End Hospital, 275 Bancroft Road, London E1 4DG, UK; n.maffulli{at}qmul.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Autologous platelet-rich plasma (PRP) is perceived to accelerate healing in muscu loskeletal injuries. PRP is increasingly used in situations that require rapid return-to play, which, in the professional sports arena, translates to fame and money. It is astonishing but understandable that the most influential stimulus for PRP therapy in the USA, years after the method had been popularised in Europe, was a February 2009 article in the lay press.1

Biological Background

Human blood platelet counts are approx imately 200 000/ml. PRP is an autologous concentration of human platelets above this in a small volume of plasma.2 Reports vary regarding the platelet concentration and different growth factors present in the PRP concentrate. Also, there are many preparation protocols, kits, centrifuges and methods to trigger platelet activation before use. The same is true for application methods, including using injectable activated PRP liquid concentrate versus implanting a fibrin scaffold, optimal timing of injection and the specific volume to use. Almost every major manufacturer in the orthopaedic and sports medicine world markets a different commercial kit. Some claim to produce a better quantity and quality of PRP than their competitors from the same amount of blood from the same patient. Costs vary tremendously: a commercial kit yields a PRP concentrate at the cost of several hundred dollars, but inhouse non-automatised techniques produce a PRP concentrate for approximately US$10. Each method to concentrate platelets leads to a different product with different biology and potential uses,3 with a high variation (3 to 27-fold) in growth factor concentration and in the kinetics of release.3,,5 Most techniques yield a PRP concentrate of approximately 10% of the blood volume taken (eg, 20 ml of whole blood would result in approximately 2 ml of PRP). These differences might be of relevance to clinical management, …

View Full Text

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.